Development of immunity-related adverse events correlates with baseline clinical factors, survival and response to anti-PD-1 treatment in patients with inoperable or metastatic melanoma

References

• Ugurel S, Rohmel J, Ascierto PA, et al. Survival of patients with advanced metastatic melanoma: the impact of novel therapies—update 2017. Eur J Cancer. 2017;83:247–257.
   PubMed Web of Science ®Google Scholar
• Cybulska-Stopa B, Skoczek M, Ziobro M, et al. Results of systemic treatment of cutaneous melanoma in inoperable stage III and IV. Współczesna Onkologia [Contemp Oncol]. 16(6):532–545.
   Google Scholar
• Cybulska-Stopa B, Piejko K, Pacholczak R, et al. Real-world treatment practice in patients with advanced melanoma. Współczesna Onkologia [Contemp Oncol]. 24(2):118–124.
   Google Scholar
• Das S, Johnson DB. Immune-related adverse events and anti-tumor efficacy of immune checkpoint inhibitors. J. Immunotherapy Cancer. 2019;7:306.
   PubMed Web of Science ®Google Scholar
• Tarhini AA, Zahoor H, Lin Y, et al. Baseline circulating IL-17 predicts toxicity while TGF-β1 and IL-10 are prognostic of relapse in ipilimumab neoadjuvant therapy of melanoma. J Immunother Cancer. 2015; 3:39.
   PubMed Web of Science ®Google Scholar
• Jaber SH, Cowen EW, Haworth LR, et al. Skin reactions in a subset of patients with stage IV melanoma treated with anti-cytotoxic T-lymphocyte antigen 4 monoclonal antibody as a single agent. Arch Dermatol. 2006;142:166.
   PubMed Web of Science ®Google Scholar
• Nakamura Y, Tanaka R, Maruyama H, et al. Correlation between blood cell count and outcome of melanoma patients treated with anti-PD-1 antibodies. Jpn J Clin Oncol. 2019;49:431.
   PubMed Web of Science ®Google Scholar
• Shahabi V, Berman D, Chasalow SD, et al. Gene expression profiling of whole blood in ipilimumab-treated patients for identification of potential biomarkers of immune-related gastrointestinal adverse events. J Transl Med. 2013;11:75.
   PubMed Web of Science ®Google Scholar
• Lim SY, Lee JH, Gide TN, et al. Circulating cytokines predict immune-related toxicity in melanoma patients receiving anti-PD-1-based immunotherapy. Clin Cancer Res. 2019;25:1557.
   PubMed Web of Science ®Google Scholar
• Weber JS, Hodi FS, Wolchok JD, et al. Safety profile of nivolumab monotherapy: a pooled analysis of patients with advanced melanoma. J Clin Oncol. 2017;35(7):785.
   PubMed Web of Science ®Google Scholar
• Eggermont AMM, Kicinski M, Blank CU, et al. Association between immune-related adverse events and recurrence-free survival among patients with stage III melanoma randomized to receive pembrolizumab or placebo: a secondary analysis of a randomized clinical trial. JAMA Oncol. 2020;6(4):519.
   PubMed Web of Science ®Google Scholar
• Topalian SL, Hodi FS, Brahmer JR, et al. Five-year survival and correlates among patients with advanced melanoma, renal cell carcinoma, or non-small cell lung cancer treated with nivolumab. JAMA Oncol. 2019;5(10):1411–1420.
   PubMed Web of Science ®Google Scholar
• Maher VE, Fernandes LL, Weinstock C, et al. Analysis of the association between adverse events and outcome in patients receiving a programmed death protein 1 or programmed death ligand 1 antibody. J Clin Oncol. 2019;37(30):2730.
   PubMed Web of Science ®Google Scholar
• Akamatsu H, Murakami E, Oyanagi J, et al. Immune-related adverse events by immune checkpoint inhibitors significantly predict durable efficacy even in responders with advanced non-small cell lung cancer. Oncologist. 2020;25(4):e679.
   PubMed Web of Science ®Google Scholar
• Suo A, Chan Y, Beaulieu C, et al. Anti-PD1-induced immune-related adverse events and survival outcomes in advanced melanoma. The Oncol. 2020;25(5):438–446.
   PubMed Web of Science ®Google Scholar
• Kichenadasse G, Miners JO, Mangoni AA, et al. Multiorgan immune-related adverse events during treatment with atezolizumab. J Natl Compr Canc Netw. 2020;18(9):1191–1199.
   PubMed Web of Science ®Google Scholar
• Bottlaender L, Amini-Adle M, Maucort-Boulch D, et al. Cutaneous adverse events: a predictor of tumour response under anti-PD-1 therapy for metastatic melanoma, a cohort analysis of 189 patients. J Eur Acad Dermatol Venereol. 2020;34(9):2096–2105.
   PubMed Web of Science ®Google Scholar
• Horvat TZ, Adel NG, Dang TO, et al. Immune-related adverse events, need for systemic immunosuppression, and effects on survival and time to treatment failure in patients with melanoma treated with ipilimumab at Memorial Sloan Kettering Cancer Center. J Clin Oncol. 2015;33(28):3193.
   PubMed Web of Science ®Google Scholar
• Ascierto PA, Simeone E, Sileni VC, et al. Clinical experience with ipilimumab 3 mg/kg: real-world efficacy and safety data from an expanded access programme cohort. J Transl Med. 2014;12:116.
   PubMed Web of Science ®Google Scholar
• Common terminology criteria for adverse events version 4.0, published: May 28, 2009 US Department of Health and Human Services National Institutes of Health, National Cancer Institute. Avaialble from: https://ctep.cancer.gov/protocoldevelopment/electronic_applications/ctc.htm#ctc_60; https://evs.nci.nih.gov/ftp1/CTCAE/CTCAE_4.03/CTCAE_4.03_2010-06-14_QuickReference_5x7.pdf
   Google Scholar
• Eisenhauer EA, Therasse P, Bogaerts J, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2009;45(2):228–247.
   PubMed Web of Science ®Google Scholar
• Hussaini S, Chehade R, Boldt RG, et al. Association between immune-related side effects and efficacy and benefit of immune checkpoint inhibitors – a systematic review and meta-analysis. Cancer Treat Rev. 2021;92:102134.
   PubMed Web of Science ®Google Scholar
• Manola J, Atkins M, Ibrahim J, et al. Prognostic factors in metastatic melanoma: a pooled analysis of Eastern Cooperative Oncology Group trials. J Clin Oncol. 2000;18(22):3782–3793.
   PubMed Web of Science ®Google Scholar
• Diem S, Kasenda B, Spain L, et al. Serum lactate dehydrogenase as an early marker for outcome in patients treated with anti-PD-1 therapy in metastatic melanoma. Br J Cancer. 2016;114(3):256–261.
   PubMed Web of Science ®Google Scholar
• Long GV, Atkinson V, Lo S, et al. Combination nivolumab and ipilimumab or nivolumab alone in melanoma brain metastases: a multicentre randomised phase 2 study. Lancet Oncol. 2018;19(5):672–681.
   PubMed Web of Science ®Google Scholar
• Gershenwald JE, Scolyer RA. Melanoma Staging: American Joint Committee on Cancer (AJCC) 8th edition and beyond. Ann Surg Oncol. 2018;25(8):2105–2110.
   PubMed Web of Science ®Google Scholar
• Cybulska-Stopa B, Pacholczak-Madej R, Kamińska-Winciorek G, et al. First-line treatment of advanced/metastatic melanoma with anti-PD-1 antibodies: multicenter experience in Poland. Immunotherapy. 2021;13(4):297–307.
   PubMed Web of Science ®Google Scholar
• https://www.gov.pl/web/zdrowie/choroby-onkologiczne (last access: 26th Feb 202).
   Google Scholar